Methods of improving cell-based therapy
AssigneeThe Regents of the University of California
InventorsNipavan Chiamvimonvat, Bruce D. Hammock
Life of this patent
Estimating the term…
Abstract
Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.
Claims18
A stent comprising a population of induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and one or more agents that increase the production and/or level of epoxygenated fatty acids, wherein the one or more agents that increase the production and/or level of epoxygenated fatty acids is:
- (1) a synthetic cis-Epoxyeicosatrienoic acid (“EET”);
- (2) an inhibitor of soluble epoxide hydrolase (“sEH”) having an IC50 of less than about 10 nM;
- or
- (3) an inhibitor of sEH comprising a primary pharmacophore selected from the group consisting of a urea, a carbamate, and an amide.
A patch comprising a population of induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and one or more agents that increase the production and/or level of epoxygenated fatty acids, wherein the one or more agents that increase the production and/or level of epoxygenated fatty acids is:
- (1) a synthetic cis-Epoxyeicosatrienoic acid (“EET”);
- (2) an inhibitor of soluble epoxide hydrolase (“sEH”) having an IC50 of less than about 10 nM;
- or
- (3) an inhibitor of sEH comprising a primary pharmacophore selected from the group consisting of a urea, a carbamate, and an amide.
Dependencies are inferred from the claim text.